

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.*

(a joint stock limited company established in the People’s Republic of China with limited liability)

(Stock Code: 8058)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement dated 22 June 2016 (the “**Announcement**”) on poll results of the annual general meeting of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (the “**Company**”) held on 22 June 2016. The Company would like to clarify that due to inadvertent mistake, the number of Shares with voting rights held by the Shareholders or their proxies who attended the AGM and the total number of Shares voted for and against the respective ordinary resolutions as set out in the table containing the poll results in the Announcement were wrongly stated to be 582,609,626 Shares. The correct number of the relevant Shares should be 443,595,762 Shares or representing 72.77 % of the entire issued share capital of the Company. The poll results in respect of the ordinary resolutions should therefore be as follows:

Ordinary resolutions		Number of Votes Cast (%)	
		For	Against
1.	to consider and approve the audited financial statements of the Company and the reports of the board (the “ Board ”) of directors (the “ Directors ”) and the auditors of the Company for the year ended 31 December 2015;	443,595,762 (100%)	0 (0%)
2.	to consider and approve the report of the supervisors of the Company for the year ended 31 December 2015;	443,595,762 (100%)	0 (0%)

Ordinary resolutions		Number of Votes Cast (%)	
		For	Against
3.	to consider and approve a final dividend of RMB0.35 per share for the year ended 31 December 2015;	443,595,762 (100%)	0 (0%)
4.	to consider and approve the Board to fix the remunerations of the Directors and supervisors of the Company;	443,417,762 (99.95%)	178,000 (0.05%)
5.	to consider and approve the appointment of HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration;	443,595,762 (100%)	0 (0%)
6.	to re-elect Mr. Liu Bioqi (劉保起) as an executive Director;	443,595,762 (100%)	0 (0%)
7.	to re-elect Ms. Li Minghua (李明華) as an executive Director;	443,595,762 (100%)	0 (0%)
8.	to re-elect Mr. Han Fengsheng (韓風生) as an executive Director;	443,595,762 (100%)	0 (0%)
9.	to re-elect Mr. Chen Yu (陳雨) as an executive Director;	443,595,762 (100%)	0 (0%)
10.	to re-elect Mr. Liu Zhenteng (劉振騰) as an executive Director;	443,595,762 (100%)	0 (0%)
11.	to re-elect Mr. Liu Zhenhai (劉振海) as a non-executive Director;	438,051,727 (98.75%)	5,544,035 (1.25%)
12.	to re-elect Mr. Foo Tin Chung (傅天忠) as an independent non-executive Director;	441,086,469 (99.43%)	2,509,293 (0.57%)
13.	to re-elect Mr. Fu Hongzheng (付宏征) as an independent non-executive Director;	443,595,762 (100%)	0 (0%)
14.	to re-elect Prof. Du Guanhua (杜冠華) as an independent non-executive Director;	441,086,469 (99.43%)	2,509,293 (0.57%)
15.	to appoint Ms. Huang Huiwen (黃慧文) as an independent non-executive Director;	443,595,762 (100%)	0 (0%)

Ordinary resolutions		Number of Votes Cast (%)	
		For	Against
16.	to re-elect Mr. Wang Jian (王健) as a supervisor; and	441,710,469 (99.57%)	1,885,293 (0.43%)
17.	to re-elect Mr. Liu Zhenfei (劉振飛) as a supervisor.	441,710,469 (99.57%)	1,885,293 (0.43%)

By order of the Board

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.*

Liu Baoqi

Chairman

PRC, 27 June 2016

As at the date of this announcement, the Board comprises 11 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors; Mr. Yin Chuangui (尹傳貴) and Mr. Liu Zhenhai (劉振海) are non-executive Directors and Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Chen Yun Zhen (陳允震) and Prof. Du Guanhua (杜冠華) are independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s designated website at: <http://shandongluoxin.quamir.com>.

* English names are translated for identification purposes only